Pulmonary manifestations of polymyositis/dermatomyositis

Robert W. Hallowell, Dana Ascherman, Sonye K. Danoff

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

Original languageEnglish
Pages (from-to)239-248
Number of pages10
JournalSeminars in Respiratory and Critical Care Medicine
Volume35
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Myositis
Dermatomyositis
Interstitial Lung Diseases
Lung
Antibodies
Amino Acyl-tRNA Synthetases
Connective Tissue Diseases
Immunosuppressive Agents
Steroids
Inflammation
Morbidity
Muscles
Mortality
Enzymes
Therapeutics
Research

Keywords

  • dermatomyositis
  • idiopathic inflammatory myopathies
  • interstitial lung disease
  • myositis-specific autoantibodies
  • nonspecific interstitial pneumonia
  • polymyositis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Pulmonary manifestations of polymyositis/dermatomyositis. / Hallowell, Robert W.; Ascherman, Dana; Danoff, Sonye K.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 35, No. 2, 01.01.2014, p. 239-248.

Research output: Contribution to journalArticle

Hallowell, Robert W. ; Ascherman, Dana ; Danoff, Sonye K. / Pulmonary manifestations of polymyositis/dermatomyositis. In: Seminars in Respiratory and Critical Care Medicine. 2014 ; Vol. 35, No. 2. pp. 239-248.
@article{6a4f34e3abc3443d827716de60a9a54d,
title = "Pulmonary manifestations of polymyositis/dermatomyositis",
abstract = "The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.",
keywords = "dermatomyositis, idiopathic inflammatory myopathies, interstitial lung disease, myositis-specific autoantibodies, nonspecific interstitial pneumonia, polymyositis",
author = "Hallowell, {Robert W.} and Dana Ascherman and Danoff, {Sonye K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1055/s-0034-1371528",
language = "English",
volume = "35",
pages = "239--248",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Pulmonary manifestations of polymyositis/dermatomyositis

AU - Hallowell, Robert W.

AU - Ascherman, Dana

AU - Danoff, Sonye K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

AB - The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

KW - dermatomyositis

KW - idiopathic inflammatory myopathies

KW - interstitial lung disease

KW - myositis-specific autoantibodies

KW - nonspecific interstitial pneumonia

KW - polymyositis

UR - http://www.scopus.com/inward/record.url?scp=84897068522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897068522&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1371528

DO - 10.1055/s-0034-1371528

M3 - Article

C2 - 24668538

AN - SCOPUS:84897068522

VL - 35

SP - 239

EP - 248

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 2

ER -